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http://www.biomedcentral.com/1471-2164/14/55RESEARCH ARTICLE Open AccessA colorectal cancer genome-wide association
study in a Spanish cohort identifies two variants
associated with colorectal cancer risk at 1p33 and
8p12
Ceres Fernandez-Rozadilla1, Jean-Baptiste Cazier2, Ian P Tomlinson2,3, Luis G Carvajal-Carmona4, Claire Palles2,
María J Lamas5, Montserrat Baiget6, Luis A López-Fernández7, Alejandro Brea-Fernández1, Anna Abulí8,9,
Luis Bujanda10, Juan Clofent11,12, Dolors Gonzalez13, Rosa Xicola14, Montserrat Andreu8, Xavier Bessa8,
Rodrigo Jover15, Xavier Llor14, The EPICOLON Consortium, Víctor Moreno16, Antoni Castells9, Ángel Carracedo1,
Sergi Castellvi-Bel9 and Clara Ruiz-Ponte1*Abstract
Background: Colorectal cancer (CRC) is a disease of complex aetiology, with much of the expected inherited risk
being due to several common low risk variants. Genome-Wide Association Studies (GWAS) have identified 20 CRC
risk variants. Nevertheless, these have only been able to explain part of the missing heritability. Moreover, these
signals have only been inspected in populations of Northern European origin.
Results: Thus, we followed the same approach in a Spanish cohort of 881 cases and 667 controls. Sixty-four
variants at 24 loci were found to be associated with CRC at p-values <10-5. We therefore evaluated the 24 loci in
another Spanish replication cohort (1481 cases and 1850 controls). Two of these SNPs, rs12080929 at 1p33
(Preplication=0.042; Ppooled=5.523x10
-03; OR (CI95%)=0.866(0.782-0.959)) and rs11987193 at 8p12 (Preplication=0.039;
Ppooled=6.985x10
-5; OR (CI95%)=0.786(0.705-0.878)) were replicated in the second Phase, although they did not
reach genome-wide statistical significance.
Conclusions: We have performed the first CRC GWAS in a Southern European population and by these means we
were able to identify two new susceptibility variants at 1p33 and 8p12 loci. These two SNPs are located near the
SLC5A9 and DUSP4 loci, respectively, which could be good functional candidates for the association signals. We
therefore believe that these two markers constitute good candidates for CRC susceptibility loci and should be
further evaluated in other larger datasets. Moreover, we highlight that were these two SNPs true susceptibility
variants, they would constitute a decrease in the CRC missing heritability fraction.
Keywords: GWAS, SNPs, Colorectal cancer, Spanish cohort, 1p33, 8p12* Correspondence: clara.ruiz.ponte@usc.es
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Even though genetic susceptibility is thought to be re-
sponsible for almost 35% of the variation in colorectal
cancer (CRC) risk [1], high penetrance mutations in
Mendelian predisposition genes, such as APC, the mis-
match repair (MMR) genes, or MUTYH are only able to
explain <5% of cases [2]. The recent advances in the field
of genetic epidemiology have validated the hypothesis
that at least part of that remaining missing susceptibility
lies in the form of multiple common low-risk variants,
each conferring a modest effect on disease risk.
Genome-wide association studies (GWAS) are one of
the most widespread methodologies for the detection of
such susceptibility loci. The procedure (in distinction to
candidate-gene association studies) offers an untargeted
strategy for the detection of new low-penetrance var-
iants, for it does not assume any a priori hypothesis on
the location of these loci. This advantage has been
proved important, since so far this kind of survey has
successfully identified 20 variants at 8q24.21, 8q23.3,
10p14, 11q23, 15q13.3, 18q21.1, 14q22.2, 16q22.1,
19q13.1, 20p12.3, 1q41, 3q26.2, 12q13.3, 20q13.33, 6p21,
11q13.3 and Xp22.2 [3-6]. The combined effect of these
variants altogether is thought to explain ~7% of the familial
cancer risk [7]. Still, there is a high proportion of genetic
contribution to CRC risk that has not been identified.
In this study we have undertaken a new screen for
CRC susceptibility variants using a GWAS approach on
our cohort of 881 CRC cases and 667 controls from the
Spanish population. The use of a Southern-European
dataset is a novelty that could lead to the identification
of new candidate loci, since all of the populations where
GWAS analyses have been conducted so far have been
of Northern European origin. Although this may provide
additional confirmation of the relationship of the 20
described variants to CRC risk in Southern Europe, we
must also consider the possibility that there may be dif-
ferences, at these or other particular loci in the genome,
between these populations.
Materials and methods
Study populations
Subjects in Phase I were 882 cases and 473 controls ascer-
tained through the EPICOLON II Project and 194 ad-
ditional controls from the Spanish National DNA bank.
The EPICOLON Consortium comprises a prospective,
multicentre and population-based epidemiology survey of
the incidence and features of CRC in the Spanish popula-
tion [8,9]. Cases were selected as patients with de novo
histologically confirmed diagnosis of colorectal adenocar-
cinoma. Patients with familial adenomatous polyposis,
Lynch syndrome or inflammatory bowel disease-related
CRC, and cases where patients or family refused to par-
ticipate in the study were excluded.Mean age for cases in Phase I was 71.20 years (SD±0.70).
Hospital-based controls were recruited through the blood
collection unit of each hospital, together with cases. All of
the controls were confirmed to have no history of cancer
or other neoplasm and no reported family history of CRC.
Controls were randomly selected and matched with cases
for hospital, sex and age (± 5 years). Population controls
from the National DNA bank were also genotyped, to
lessen the deficit of controls. They were matched for sex,
age (± 10 years) and geographical origin of the sample
with the remaining cases. Both cases and controls were of
European ancestry and from Spain (stated, when possible,
as all four grandparents being Spanish).
Samples in Phase II consisted of 1436 CRC patients
and 1780 controls: samples from Hospital Sant Pau were
125 CRC patients from a previously described cohort
[10]; the Hospital Gregorio Marañón dataset consisted
of 104 CRC patients participating in a pharmagogenetic
survey; Catalan Institute of Oncology (ICO) samples
were 439 patients who belonged to the Bellvitge Colo-
rectal Cancer Study; the CHUS hospital in Santiago
de Compostela was a subsample of 153 participants
included in a pharmacogenetic study; 105 CRC cases
and 1330 controls came from the Spanish National
DNA bank; and 510 CRC cases and 450 DNA controls
belonged to the EPICOLON I Project [8]. Of the cases,
60.4% were male and 39.6% female. Controls were
matched for gender. Age mean was 69.61 (SD±0.59) for
cases and 52.00 (SD±0.58) for controls. Gender and hos-
pital distribution of samples for case and control groups
on both Phases is shown on (Additional file 1: Table S1).
DNA was obtained from frozen peripheral blood by
standard extraction procedures for all samples. Cases
and controls were extracted in mixed batches to avoid
bias.
Ethical standards
The study was approved by the “Comité Ético de Investi-
gación Clínica de Galicia”, and each of the institutional
review boards of the participating hospitals. All samples
were obtained with written informed consent reviewed
by the ethical board of the corresponding hospital, in ac-
cordance with the tenets of the Declaration of Helsinki.
SNP genotyping and QC
Affymetrix array 6.0 (Affymetrix, CA, USA), which
includes probes for almost 1M SNP markers, was chosen
to obtain genome-wide coverage for Phase I genotyping.
Genotype calling for Affymetrix 6.0 was performed with
the Birdseed algorithm, included within Birdsuite v1.4
[11]. Samples were organized in 23 batches of 16<n<99
according to hospital of origin for computational pur-
poses. We obtained valid genotypes for 909 622 SNPs by
these means. Quality control of the data, performed
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both SNPs and samples with genotyping success rates
<99% (N=5984 for SNPs and N=0 for samples) and sam-
ples with discordant gender between clinical recorded
data and Affymetrix-asigned sex (N=7). Hardy-Weinberg
equilibrium (HWE) was evaluated and markers with
PHWE<1x10
-4 in controls were removed from further
analyses (N=6984). SNPs with MAFs below 0.05 (N=221
799) were also eliminated due to low power to detect
true signals and to avoid unnecessary noise. Finally, dif-
ferential missingness between cases and controls was
also accounted for by excluding markers with p-values
below 1x10-4 (N=137). This test compares genotyping
error rates for the affected vs. unaffected groups in order
to avoid an increase in false positive findings due to this
bias. Finally, SNPs with poor clustering were also
excluded after visualisation with Evoker (briefly, asso-
ciated SNPs at a selected threshold were selected for
comparison of the two intensity channels against each
other to manually check the proper assignment of the
genotype-calling algorithm) [13]. A total of 674 718
SNPs remained after this filtering.
To address the possibility of underlying population strati-
fication, Principal Component Analysis (PCA) on a subset
of 98 986 randomly chosen independent SNPs (pairwise
r2<0.1) was also performed on the full Phase I cohort using
the EIGENSOFT smartpca software [14]. Long-range LD
regions, as described by Price et al. [15], were also removed
from this analysis. Outliers, taken as samples spread on
principal components 1 and 2 were removed from subse-
quent analyses, since they deviated from the main cloud.
No evidence was found of population differences between
cases and controls for the first 10 components of the PCA
analysis, as stated in the Tracy-Widsom test (Figure 1a).
Other potentially confounding variables, such as markers
typed using the Nsp or Sty restriction endonucleases, hos-
pital of collection, genotyping plate, or geographical origin
of the samples were also checked for as sources for stratifi-
cation (data not shown). All results were concordant with
the original assumption of a single originating population
except for hospital of origin. When considered as a con-
founding variable, the EPICOLON cohort clustered into
three separate subgroups: samples from the Donostia hos-
pital (VAS dataset), the only collection centre for the
Basque Country region (North of Spain), samples from the
Meixoeiro hospital (GAL dataset), the single collection
point in Galicia (NW Spain), and all others (REST dataset)
(Figure 1b). An additional PCA comprising the full Phase I
cohort and the HapMap3 populations (all ancestries) was
also performed to illustrate the clustering of these popu-
lations (Figure 1c) [16]. EPICOLON II samples that clus-
tered away from the European end of the plot (showing
evidence of non-European ancestry) were excluded from
further analyses.The final case dataset comprised 1477 samples (848
cases and 629 controls). The total count per subgroup
was 167 for VAS, 366 for GAL and 944 for REST.
Genotyping in Phase II was conducted by Sequenom
MassARRAY technology (Sequenom Inc. San Diego, CA,
USA). rs7087402 at 10q23.31 could not be included in the
analyses for genotyping design reasons. Quality control
was performed with PLINK similarly to Phase I. Genoty-
ping for both Phases was performed at the Santiago de
Compostela node of the Spanish Genotyping Centre.
Statistical analysis
Association analysis was assessed as a 1°-of-freedom χ2 al-
lelic test for each of the three subgroups independently for
Phase I, and for second Phase replication, with PLINK
[12]. The adequacy of the distribution of p-values was
evaluated using quantile-quantile (Q-Q) plots of test
statistics. Meta-analysis was also conducted using PLINK
in Phase I. The method is based on a Mantel-Haenszel
approach for data pooling. Cochran´s Q statistic and the
I2 heterogeneity index were also estimated to account for
inter-population heterogeneity between groups, which
was defined as I2>75% [17,18]. For markers above this
threshold, a random-effects model was considered, whereas
fixed-effect results were otherwise reported. Risks (odds
ratios, ORs) with 95% confidence intervals (CIs) associated
with each marker were then estimated assuming the appro-
priate model. Phase II analyses were adjusted by age, given
the mean differences between the case and control popula-
tions for these cohorts. Pooled analysis was performed
by logistic regression, considering genotyping Phase and
population subgroup as covariates. Associations by pheno-
type (age at diagnosis, MSI status, tumour location, pres-
ence of previous adenomas, family history of CRC and sex)
were examined by logistic regression in case-only analyses
for the two associated SNPs (Additional file 1: Table S2).
Additional statistical calculations and plots were performed
using R [19].
Imputation
Imputation between the two recombination hotspots
encompassing each of the 24 loci that showed evidence
of association in Phase I was accomplished with Impute
v2 using two reference panels: 1000 Genomes Project
(b36) for wide coverage, and HapMap3 (r2 b36) for deep
coverage [16,20,21]. Results from the imputation were
later tested for association with SNPTEST [20]. Imput-
ation results were filtered by minor allele frequency
(MAF) of the markers (SNPs with MAFs<5% were
excluded, since the procedure generates genotypes for a
high number of rare variants that could give spurious as-
sociation results), by missing data proportion (set to a
5% max), and the frequentist-add-proper-info column of
the output. This latter statistic is the ratio of the
Figure 1 PCA analysis on the EPICOLON cohort. (a) filtered data by case/control; (b) filtered data by hospital of origin; (c) EPICOLON and
HapMap3 populations. Significant differences may be seen in section b with Meixoeiro and Donosti hospitals deviating from the main cloud.
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expected binomial variance p(1-p) at HWE, where p is
the observed allele frequency from HapMap [22]. Opti-
mal values should be within the (0.4-1) range and
provide a measure for quality and accuracy of the imput-
ation. Since the proportion of cases and controls devi-
ates significantly from the standard 1:1, we alsoconsidered the possibility that the imputed genotype
probabilities for each marker were different in both sub-
sets. Since IMPUTE gives back the imputation results as
a probability for each genotype, we decided to filter out
SNPs for which the probability of two out of the three
genotypes was ≥25% (i.e. the genotype in this sample
was not clear) in at least 5% of the cases or the controls.
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imputation has been inaccurate. Imputation results were
plotted with the SNAP on-line tool [23].
Results
Stratification within the EPICOLON cohort
We observed using PCA that there was a batch effect
due to differences by hospital at which sample had been
collected, thereby dividing the EPICOLON cohort into
three separate subgroups. We thus proceeded on the
basis that each cluster - the GAL, VAS and REST case-
control groups - was a separate sample set. Association
results were then obtained for each of the subpopula-
tions separately and then meta-analysed. Q-Q plots for
the subgroups (after QC) showed an improvement in
the systematic inflation for the distribution of the associ-
ation p-values for the GAL, REST and VAS subgroups
(Additional file 2: Figures S1A, 1B and 1C. respectively).
Lambda genomic factor calculations (1.04192, 1.02323Table 1 Association results for phase I
LOCUS SNP BP Allele MAF
1p33 rs12080929 48.208.735 C 0.249
2p25.2 rs4669394 5.541.078 C 0.049
2p24.1 rs1554267 22.284.451 A 0.457
3p21.31 rs8180040 47.363.951 A 0.366
3q12-q13 rs6438550 121.019.507 G 0.038
5q35.1 rs11740081 172.707.280 A 0.123
6q16.1 rs12213685 99.288.865 G 0.163
6q23.1 rs12199765 131.192.418 A 0.268
8p12 rs11996339 29.386.099 C 0.351
8p12 rs11987193 29.391.927 A 0.237
8p12 rs12548021 29.400.381 G 0.378
8q13.3 rs17788534 72.697.475 C 0.198
8q22.1 rs3104964 96.664.912 C 0.452
10p15.1 rs7074607 5.623.371 A 0.151
10q23.31 rs7087402 92.760.125 A 0.527
12q24.31 rs568489 119.578.624 G 0.478
13q32.3 rs17196583 99.624.356 A 0.201
14q31.3 rs7148493 85.094.169 G 0.431
14q32.12 rs8177528 92.247.404 A 0.407
15q21.3 rs4644804 52.164.106 A 0.387
15q25.3 rs16941001 86.249.170 A 0.101
17p13.2 rs16954697 5.297.637 A 0.150
17p12 rs9898623 13.255.126 A 0.045
18p11.22 rs10502376 8.579.765 A 0.426
18q21.2 rs2958182 51.300.019 A 0.330
22q12.3 rs956119 34.582.213 G 0.064
Main features of the SNPs associated in Phase I. Only the top associated SNPs at ea
to NCBI36/hg18.and 1.02292 for GAL, VAS and REST, respectively) were
consistent with no evidences of an increased false dis-
covery rate. Additional file 2: Figure S1D represents the
Q-Q plot distribution after meta-analysis of the three
subpopulations. Some SNPs still seem to deviate from
the expected distribution. These were later discovered to
be artefacts of the calling procedure and were further
removed with Evoker.
Association analyses
We found 64 SNPs at 24 genomic loci SNPs associated
with CRC risk at P≤10-4 (lowest p-value=9,7x10-8 for
rs11996339 at 8p12) (Table 1). Notably, I2 heterogeneity
values for the three subgroups (GAL, VAS, REST) were
all 0 for these markers, thereby reflecting homogeneity
in these associated SNPs.
Using imputation, we examined the LD blocks defined
by recombination hotspots (as obtained from Haploview
in the CEU+TSI HapMap3-r2 populations) around thecases MAF controls OR (95% CI) P value
0.312 0.731 (0.621-0.860) 9.447E-05
0.087 0.731 (0.622-0.860) 3.113E-05
0.371 1.429 (1.231-1.658) 3.139E-06
0.454 0.695 (0.599-0.806) 1.595E-06
0.072 0.511 (0.369-0.709) 6.789E-05
0.188 0.604 (0.494-0.741) 6.789E-05
0.106 1.643 (1.313-2.042) 1.136E-05
0.202 1.434 (1.217-1.726) 5.428E-05
0.448 0.667 (0.574-0.774) 9.697E-08
0.309 0.691 (0.589-0.818) 9.752E-06
0.289 1.478 (1.279-1.749) 1.073E-06
0.141 1.509 (1.237-1.841) 7.903E-05
0.367 1.422 (1.225-1.652) 5.201E-06
0.1025 1.556 (1.242-1.949) 8.901E-05
0.4436 1.398 (1.208-1.619) 5.202E-06
0.397 1.391 (1.200-1.612) 1.650E-05
0.145 1.488 (1.222-1.812) 7.307E-05
0.362 1.332 (1.147-1.548) 9.823E-05
0.335 1.367 (1.174-1.591) 5.471E-05
0.316 1.368 (1.173-1.596) 5.403E-05
0.059 1.806 (1.361-2.396) 3.704E-05
0.098 1.625 (1.293-2.044) 2.522E-05
0.085 0.512 (0.378-0.692) 1.625E-05
0.496 0.753 (0.651-0.872) 9.819E-05
0.261 1.392 (1.184-1.636) 9.792E-05
0.104 0.591 (0.453-0.770) 9.193E-05
ch of the 24 independent loci is shown. All genomic positions correspond
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Additional file 1: Table S3 provides a summary of the loci
and extent of the imputed regions. This analysis improved
the association at 4 of the 24 loci: 1p33 (best SNP
rs12060081); 14q31.3 (rs2057115); 15q21.3 (rs7176932);
and 22q12.3 (rs17725348) (Additional file 3: Figure S2).
Replication
The ±1Mb regions flanking all 24 loci with evidence of as-
sociation in Phase I were examined in the United Kingdom
CORGI GWAS cohort through proxy SNP assessment
[24]. Only 5 of these locations showed to have some
CORGI associated SNP at an established p value threshold
of P≤10-4. However, LD analysis (in HapMap3-r2 CEU
+TSI available data) showed them all to be independent
signals (data not shown). Therefore, our attempt to repli-
cate the association signals in silico was not successful for
any of the variants.
Since there has been extensive literature on the diffe-
rences amongst Northern and Southern European popu-
lations [25-28], we decided to perform a further PCA on
15,000 independent markers in order to compare allelic
frequencies among the EPICOLON controls, the Hap-
Map3 CEU and TSI populations, and the Wellcome
Trust Case Control Consortium (WTCCC2) control
cohorts [29]. This analysis effectively separated the
Northern and Southern-European populations (Figure 2).
Given this evidence, we decided to attempt replication
of the best-associated markers (whether directly geno-
typed or imputed) at these 24 loci in an independent
Spanish cohort (Phase II). Thirty-two SNPs were finally
selected to be genotyped at this Phase II according to
LD measures at the 24 loci and experimental design.Figure 2 PCA analysis on the WTCCC (Affymetrix 6.0 data), HapMap3
independent markers was used to perform the analysis. The first eigenvectThe markers genotyped at each locus and their association
values in the replication phase are described in Table 2.
Two out of the replicated 32 SNPs, rs12080929
(chromosome 1p33) and rs11987193 (chromosome 8p12)
were successfully replicated at a nominal level of p<0.05 in
this second Phase (P=0.044, OR=0.867 (0.722-0.994) and
P=0.039, OR=0.847 (0.724-0.992), respectively). Although
the association signals were very modest, pooled analysis
of the data from both phases was consistent with the pres-
ence of a potential CRC susceptibility variant in these
locations (pooled p values P=5.523x10-3 and P=6.985x10-5,
respectively), and the signals remained significant across
population subgroups (with the exception of the smallest
VAS dataset) (Figure 3). Another two variants at locus
14q31.3 were significant in Phase II, but their OR were in
different directions for each of the Phases, thereby reflect-
ing a potential false positive event in Phase I. Given the
marker sizes, this finding is entirely compatible with a ran-
dom positive finding at a significance level of 0.05. With
regards to phenotype analysis, rs12080929 seemed to be
slightly overrepresented in males vs. females (P=0.042,
OR=0.771 (0.600-0.991)), whereas rs11987193 was more
prevalent in rectal cancers (P=0.028, OR=1.327 (1.031-
1.707)). None of the other variables used in the subgroup
analyses provided statistically significant results (Addi-
tional file 1: Table S2). It is also remarkable that none of
the remaining three SNPs genotyped at these two loci
(rs12080061 at 1p33, and rs11996339 and rs12548021 at
8p12) appeared to be replicated in this second phase, al-
though rs12080061 showed a borderline p value in Phase
II (P=0.087); in the case of rs11996339 and rs12548021 at
8p12 r-squared LD values among the three SNPs seem to
show that the three markers are independent.CEU and TSI and EPICOLON populations. A set of 15 000
or separates the Northern and Southern European populations.
Table 2 Association results for phase II and pooled analysis
LOCUS SNP P PHASE II OR (95% CI) POOLED P POOLED OR (95% CI)
1p33 rs12080929 0.042 0.867 (0.722-0.994) 5.523E-03 0.866 (0.782-0.959)
1p33 rs12080061* 0.087 0.870 (0.743-1.020) 6.418E-05 0.793 (0.623-0.874)
2p25.2 rs4669394 0.736 1.038 (0.837-1.286) 6.693E-03 0.763 (0.627-0.928)
2p24.1 rs1554267 0.175 0.906 (0.785-1.045) 0.021 1.123 (1.018-1.240)
3p21.31 rs8180040 0.106 0.887 (0.767-1.026) 2.163E-06 0-784 (0-709-0-867)
3q12-q13 rs6438550 0.944 1.012 (0.731-1.400) 4.843E-03 0.723 (0.576-0.906)
5q35.1 rs11740081 0.508 0.935 (0.764-1.142) 4.772E-04 0.783 (0.683-0.898)
6q16.1 rs12213685 0.875 0.987 (0.842-1.157) 6.627E-03 1.220 (1.058-1.407)
6q16.1 rs4538713* 0.939 0.992 (0.804-1.224) 6.282E-04 0.702 (0.627-0.837)
6q23.1 rs12199765 0.231 1.108 (0.93-1.309) 2.693E-05 1.281 (1.141-1.438)
8p12 rs11996339 0.690 0.971 (0.842-1.120) 6.985E-05 0.817 (02739-0.903)
8p12 rs11987193 0.039 0.847 (0.724-0.992) 6.985E-05 0.786 (0.705-0.878)
8p12 rs12548021 0.234 1.095 (0.943-1.271) 2.587E-06 1.28 (1.155-1.418)
8q13.3 rs17788534 0.471 1.073 (0.885-1.301) 8.040E-04 1.249 (1.097-1.422)
8q22.1 rs3104964 0.081 1.139 (0.984-1.317) 4.239E-06 1.265 (1.144-1.398)
10p15.1 rs7074607 0.174 0.867 (0.705-1.065) 0.090 1.131 (0.981-1.305)
10q23.31 rs7087402 NA NA NA NA
12q24.31 rs568489 0.701 1.022 (0.916-1.139) 1.197E-03 1.178 (1.067-1.300)
12q24.31 rs2686555 0.913 1.006 (0.903-1.121) 3.619E-03 1.158 (1.049-1.278)
13q32.3 rs17196583 0.270 0.903 (0.752-1.083) 0.0455 1.136 (1.003-1.288)
14q31.3 rs2057115 0.030 0.791 (0.639-0.977) 0.395 1.065 (0.921-1.231)
14q31.3 rs7148493 0.024 0.843 (0.727-0.977) 0.308 1.054 (0.923-1.165)
14q32.12 rs8177528 0.423 1.056 (0.910-1.225) 1.163E-03 1.183 (1.069-1.309)
15q21.3 rs4644804 0.528 1.037 (0.927-1.159) 0.011 1.139 (1.030-1.259)
15q25.3 rs16941001 0.484 1.067 (0.891-1.277) 5.457E-04 1.351 (1.139-1.603)
15q25.3 rs16941002* 0.560 1.055 (0.880-1.265) 0.127 1.143 (0.952-1.345)
17p13.2 rs16954697 0.280 1.119 (0.913-1.372) 3.168E-04 1.301 (1.127-1.501)
17p12 rs9898623 0.449 0.926 (0.757-1.131) 1.526E-03 0.734 (0.607-0.889)
18p11.22 rs10502376 0.986 0.973 (0.842-1.125) 0.011 0.880 (0.797-0.971)
18q21.2 rs2958182 0.714 1.001 (0.861-1.164) 1.831E-03 1.181 (1.064-1.311)
22q12.3 rs956119 0.369 0.897 (0.708-1.137) 5.911E-03 0.785 (0.660-0.933)
22q12.3 rs17725348* 0.273 0.875 (0.690-1.110) 3.976E-04 0.702 (0.629-0.895)
*Denotes imputed SNPs; NA: not available.
P-values and ORs for the SNPs genotyped in Phase II. All genomic positions correspond to NCBI36/hg18.
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In addition to the search of new susceptibility variants,
we also investigated the association signals for 19 of the
known CRC susceptibility variants [3-5]. rs5934683 on
Xp22.2 could not be evaluated due to the fact that sexual
chromosome data need to be processed differently. Con-
sidering these markers were described from Illumina
array tagSNP panels, most of them were not directly
genotyped in our chip; therefore we proceeded with the
evaluation of the association signals by considering the
closest related proxy SNP (Table 3). Direct evidence of
replication (taken as the presence of an associated SNPwith one-tailed P<0.05 in the same LD block as the
described tagSNP) was found for 2 of the SNPs (Table 3).
The remaining loci, although not significant, showed
ORs in the same directions as those described in the lit-
erature. We must however highlight that some of these
SNPs (rs4444235 and rs1957636 at 14q22 and rs961253
andrs4813802 at 20p12) have already been found to
present differences in Northern and Southern European
populations, a fact that is consistent with our study not
being able to replicate the association signals at these
loci [28]. Imputation of the LD regions around these asso-
ciated loci was conducted to search for an enhancing of
Figure 3 Forest Plots for rs12080929 and rs11987193. The
figure represents the odds ratios and 95% confidence intervals for
the two markers in all 3 populations subgroups from Phase I, the
Phase II replication dataset and the pooled analysis of both Phases.
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except for locus 15q13, for which an imputed SNP,
rs16970016, 15kb upstream the GREM1 gene, scored the
best p value in our dataset (P=9.847x10-5). This SNP has a
good pairwise relationship with the formerly described
rs4779584 (r2=0.882) (data not shown).
Discussion
Genome-wide association studies have so far successfully
identified 20 CRC susceptibility SNPs [3-6]. Although
this has been a significant improvement in the unrave-
lling of the genetic basis of the disease, these variants
alone do not completely explain all the inherited varia-
tion that has been attributed to CRC.
Following the lead of the previous studies, we
addressed the issue of trying to detect new colorectal
cancer susceptibility variants through the performance
of a GWAS in a Spanish cohort. This was the first at-
tempt to perform a CRC GWAS in a Southern European
population. By these means, we were able to positively
identify two new candidate variants that have shown
good evidence of association with CRC risk: rs12080929
at 1p33 and rs11987193, at 8p12.Previous susceptibility loci
During the analysis, we were faced with the fact that, al-
though there were no differences between case and con-
trol populations, there was a significant stratification
issue determined by the hospital of origin of the sam-
ples. Because of this, the analyses had to be modified to
match our case scenario without losing significant
power. Nevertheless, the substructure in our cohort did
not seem to greatly affect outcome quality. The evalu-
ation on the 19 out of 20 already-described signals
achieved direct replication for 2 of the loci (11q23 and
18q21). The other 17 markers did not show evidence of
association, probably due to the lack of power in our co-
hort to detect such moderate effects. Nevertheless, OR
directions were consistent with those previously pub-
lished. We must highlight at this point that the best-
associated markers for these regions did not always
match with the best proxy for the already described
SNPs. This would make sense if we consider that any
given GWAS relies on an indirect approach, and we
would expect the associated SNPs to only be tagging the
real causative variant. Results for allele frequencies and
ORs seem consistent with the bibliography [3-5]. We con-
sider the replication of these loci an important achieve-
ment, since the majority of these association signals had
not been previously evaluated in Southern European
cohorts (with the notable exception of rs16892766 at
8q23.3, rs10795668 at 10p14, rs3802842 at 11q23,
rs4779584 at 15q13, rs4444235 and rs1957636 at 14q22,
and rs961253 and rs4813802 at 20p12 [5,28,30,31].
Spanish GWAS results
The association analysis in itself provided with positive
results for 24 different genomic loci at a p-value <0.0001.
A first attempt at replication was aimed by inspection of
these association signals on the British CORGI cohort
[24]. However, none of the signals seemed to be shared
between datasets. This lack of replication could be due to
both false positive findings and artefacts from the calling
algorithm, or to real differences between both populations
leading to dissimilar abilities to tag the real causative vari-
ant [32]. The latter option has been recently proven to be
possible, since differences in MAFs between Northern and
Southern European populations have been described for
SNPs rs4444235, rs1957636, rs961253 and rs4813802 [28].
A PCA analysis on the EPICOLON samples compared
to the WTCCC control cohorts and the data from the
HapMap3 CEU and TSI populations showed clear diffe-
rentiation between the Northern and Southern European
populations. Although not significant, SNP loadings also
evidenced principal component 3 to be exclusively
driven by a region of chromosome 8 (7.2-12Mb) where a
common inversion is known to occur [33,34], whereas
Eigenvectors 4-7 were driven by the HLA-A locus in the
Table 3 Replication results for the already-described loci
SNP REF LOCUS REPORTED ALLELE REPORTED MAF ALLELIC OR (95% CI) BEST PROXY AFFY 6.0 R2 OR (95% CI) EPICOLON
P value
rs6687758 1q41 G 0.2 1.09 (1.06-1.12) rs6691195 1 1.10 (0.92-1.33) 0.291
rs6691170 1q41 T 0.34 1.06 (1.03-1.09) rs11579490 0.902 1.00 (0.86-1.17) 0.974
rs10936599 3q26 T 0.24 0.93 (0.91-0.96) rs7621631 1 0.99 (0.83-1.19) 0.970
rs16892766 8q23 C 0.07 1.32 (1.21-1.44) rs2437844 0.925 1.13 (0.87-1.46) 0.360
rs6983267 8q24 T 0.48 0.83 (0.79-0.87) rs6983267 - 0.87 (0.75-1.01) 0.065
rs10795668 10p14 A 0.33 0.91 (0.86-0.96) rs706771 0.896 0.89 (0.76-1.04) 0.15
rs3802842 11q23 C 0.29 1.21 (1.15-1.27) rs3802840 1 1.19 (1.01-1.40) 0.037
rs11169552 12q13 T 0.26 0.92 (0.90-0.95) rs11169544 1 0.99 (0.83-1.18) 0.891
rs7136702 12q13 T 0.35 1.06 (1.03-1.09) rs7136702 - 1.14 (0.98-1.33) 0.0806
rs4444235 14q22 C 0.46 1.12 (1.07-1.18) rs11623717 0.838 1.01 (0.88-1.17) 0.859
rs1957636 14q22 A 0.39 1.08 (1.06-1.11) rs4901475 0.932 1.16 (0.99-1.34) 0.153
rs16969681 15q13 T 0.09 1.18 (1.11-1.25) rs16969344 1 1.21 (0.96-1.53) 0.103
rs11632715 15q13 A 0.46 1.12 (1.08-1.16) rs12592288 0.524 1.04 (0.81-1.12) 0.589
rs9929218 16q22 A 0.29 0.88 (0.83-0.92) rs7186084 1 0.94 (0.80-1.10) 0.439
rs4939827 18q21 C 0.47 0.85 (0.81-0.89) rs7226855 1 0.82 (0.71-0.95) 8.204E-03
rs10411210 19q13 T 0.10 0.79 (0.72-0.86) rs7252505 0.831 0.90 (0.72-1.13) 0.363
rs961253 20p12 A 0.36 1.13 (1.08-1.19) rs5005940 1 1.11 (0.92-1.26) 0.349
rs4813802 20p12 G 0.36 1.09 (1.06-1.12) rs4813802 - 1.07 (0.91-1.25) 0.433
rs4925386 20q13 T 0.32 0.93 (0.91-0.95) rs4925386 - 0.96 (0.82-1.12) 0.61
Association data for the 19 CRC risk variants (rs5934683 at Xp22.2 is not included). In bold two of the SNPs that showed direct evidences of association at a
nominal p value<0.05.
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also described as highly variable between populations
[35]. Given this evidence, we proceeded on to replicate
these 24 loci in an independent Spanish cohort.
SNPs rs12080929 and rs11987193 were successfully repli-
cated in Phase II analyses. The former SNP, rs12080929 is
located on an intronic position within hypothetical locus
LOC388630 on 1p33. This predicted gene is believed to
code for a single-pass type I membrane protein. Moreover,
it lies 252kb upstream the SLC5A9 gene, a member of the
solute carrier family, which could be a feasible regulation
target. SLC proteins constitute good candidates to
harbour CRC susceptibility loci, since some family mem-
bers have been proven to act as tumour suppressors. In
fact, the SLC5A8 gene is properly expressed in normal
colon, but silenced in aberrant crypt foci through gene
methylation [36].
The rs11987193 SNP is located in the 8p12 locus, 128kb
downstream DUSP4. This gene is a member of the dual
kinase phosphatase family, which are well-known tumour
suppressors too [37]. They act through the downregula-
tion of MAP kinases, thus preventing cellular proliferation
and differentiation. Deletions in this gene have already
been described to happen in other types of cancers, such
as those of the breast and lung. In the case of CRC,
DUSP4 expression appears to be modulated by KRASmutations [38-40]. Moreover, it has recently been
described that DUSP4 expression is associated with
microsatellite instability in CRC and causes increased cell
proliferation [41].
The fact that these two SNPs were not replicated during
the initial assessment of the association signals in the
CORGI cohort, together with the North-South discrepan-
cies seen in the PCA analysis, could be a sign of differences
in the tagging of the real causative variant amongst popula-
tions. Even when Europeans are presumed to be genetically
homogeneous, it is not unrealistic to believe that punctual
LD variations may be actually happening within popula-
tions, and that these may constitute a certain impediment
in our ability to replicate association signals [25,26].
Although none of the markers reached a final genome-
wide significant p value, two of the SNPs in our study
(rs12080929 and rs11987193) were favourably replicated
in the second Phase and pooled analysis. However the
limitations of this study (namely the modest sample sizes,
further power restrictions also derived from the case-
control age bias in Phase II and the potential differences
between northern and southern European populations),
we believe these two regions are good candidates for CRC
susceptibility loci. The peculiarities of these loci, parti-
cularly those relating to potential Northern-Southern
European differences, may have important repercussions
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tification of the functional variant is of uttermost impor-
tance. Finer mapping of the locus, coupled with additional
replication efforts in larger cohorts will be needed to fully
ascertain the relationship between these variants and dis-
ease. Moreover, it is important to highlight that, were these
two SNPs true susceptibility variants, they would constitute
a decrease in the CRC missing heritability fraction. This is
an essential point in our road towards the identification of
high-risk individuals within populations [7].
Conclusions
The novelty of this study was the use of a Southern-
European dataset to perform a CRC GWAS study that led
to the identification of two new candidate variants:
rs12080929 at 1p33 and rs11987193 at 8p12. These two
SNPs are located near the SLC5A9 and DUSP4 loci, re-
spectively. Some family members of the SLC proteins, as
well as the DUSP gene, have been proven to act as tumour
suppressors. Therefore, both of them could be good func-
tional candidates for the association signals. Finer mapping
and further replication in larger cohorts will be needed to
ascertain their relationship with CRC susceptibility. The pe-
culiarities of these loci, particularly those relating to poten-
tial Northern-Southern European differences, may have
important repercussions on subsequent analyses.
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